This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A second look: Discussing commercial use of Filspari (sparsentan) and Vanrafia (atrasentan) in IgAN

Ticker(s): TVTX, NVS

Who's the expert?

Institution: Allina Health

  • Board certified in Internal medicine and nephrology with an American Hypertension Specialist Certification(AHSC)
  • Specializes in kidney transplantation and transplantation immunology while having close to 20 publications in the area involving kidney diseases
  • Manages 24-30 IgAN patients and currently has 12 on Filspari. 

Interview Questions
Q1.

How many patients do you have on Filspari?

Added By: wilson_admin
Q2.

How do you think you will use Vanrafia going forward?

Added By: wilson_admin
Q3.

How important are these medications in IgAN relative to what was available prior to their approvals?

Added By: wilson_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.